Physician profile
Michelle E Papa
NPI 1013042431
$23,480.70
in general payments reported to CMS, 2019-2025
76 companies · $3,612 in 2025
The $3,612 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,967 · 2020: $1,077 · 2021: $4,566 · 2022: $3,519 · 2023: $5,076 · 2024: $3,664 · 2025: $3,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,852 · Consulting Fee: $2,385 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,851.53 |
| Consulting Fee | $2,385.00 |
| Education | $114.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,208.45 | 2019-2025 | |
| Novo Nordisk INC | $2,624.19 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,720.99 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,332.60 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,036.66 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Pfizer INC. | $907.67 | 2019-2025 | |
| Lilly USA, LLC | $854.84 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk As | $645.00 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $639.30 | 2021-2024 | Qelbree, Qelbree, Xyosted |
| Otsuka America Pharmaceutical, INC. | $586.80 | 2019-2025 | Rexulti, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $548.30 | 2020-2025 | Caplyta |
| Alkermes, INC. | $532.46 | 2019-2025 | Lybalvi, Aristada |
| Sunovion Pharmaceuticals INC. | $506.43 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $453.23 | 2019-2025 | Spravato, Xarelto, Invega |
| Harmony Biosciences LLC | $405.98 | 2023-2025 | Wakix |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $362.35 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $350.98 | 2019-2025 | Trintellix |
| Abbott Laboratories | $306.50 | 2021-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $284.25 | 2019-2025 | Verquvo, Lagevrio, Steglatro |
| Ardelyx, INC. | $283.08 | 2023-2025 | Ibsrela |
| Astellas Pharma US INC | $277.84 | 2019-2025 | Veozah, Myrbetriq |
| Scilex Pharmaceuticals INC. | $252.99 | 2019-2024 | Ztlido |
| Amgen INC. | $247.57 | 2019-2025 | Otezla, Repatha, Evenity |
| Corcept Therapeutics | $230.99 | 2024-2025 | Korlym |
| Avanir Pharmaceuticals, INC. | $229.10 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $216.31 | 2021-2025 | |
| Indivior INC. | $213.00 | 2019-2025 | Sublocade |
| Xeris Pharmaceuticals, INC. | $204.18 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.34 | 2019-2025 | Relistor, Xifaxan |
| Axsome Therapeutics, INC. | $190.39 | 2023-2025 | Auvelity, Sunosi |
| Biohaven Pharmaceutical Holding Company LTD. | $148.10 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $137.27 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Neurocrine Biosciences, INC. | $135.00 | 2022-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $132.76 | 2022-2025 | Fanapt, Hetlioz |
| Sanofi-Aventis U.S. LLC | $114.08 | 2019-2022 | |
| Lundbeck LLC | $113.34 | 2023-2025 | Vyepti, Rexulti |
| Antares Pharma, INC. | $102.58 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Neos Therapeutics, LP | $90.71 | 2019 | |
| Braeburn INC. | $85.15 | 2023-2025 | Brixadi |
| Phathom Pharmaceuticals, INC. | $81.64 | 2024-2025 | Voquezna |
| Mylan Specialty L.P. | $75.25 | 2021-2023 | Yupelri |
| Sumitomo Pharma America, INC. | $75.01 | 2023-2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $73.80 | 2023-2024 | Quviviq |
| Amarin Pharma, INC. | $70.83 | 2020 | |
| Gilead Sciences, INC. | $69.62 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $62.45 | 2021 | |
| Arbor Pharmaceuticals, INC. | $59.58 | 2019-2020 | |
| Allergan, INC. | $58.64 | 2019-2020 | |
| Seqirus USA INC | $58.25 | 2021-2024 | Fluad, Flucelvax |
| Novartis Pharmaceuticals Corporation | $57.37 | 2023-2024 | |
| Almatica Pharma LLC | $54.09 | 2021-2023 | Gralise |
| Verona Pharma, INC. | $53.81 | 2025 | Ohtuvayre |
| Corium, LLC | $52.62 | 2023 | Azstarys |
| Eisai INC. | $48.80 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $45.36 | 2025 | Cobenfy |
| Avadel Cns Pharmaceuticals, LLC | $42.88 | 2024 | Lumryz |
| Clarus Therapeutics INC. | $37.32 | 2021 | |
| Esperion Therapeutics, INC. | $37.19 | 2025 | Nexletol |
| Exact Sciences Corporation | $37.01 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Endo Pharmaceuticals INC. | $36.11 | 2019-2021 | |
| Optinose US, INC. | $35.02 | 2024 | |
| Jazz Pharmaceuticals INC. | $33.88 | 2020-2021 | |
| Acerus Pharmaceuticals Corporation | $33.85 | 2021 | |
| Tactile Systems Technology INC | $31.78 | 2024 | Entre Plus, Flexitouch Plus |
| Tolmar, INC. | $31.30 | 2023 | |
| Nestle Healthcare Nutrition INC. | $27.98 | 2022 | |
| Tris Pharma INC | $27.34 | 2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $24.33 | 2019 | |
| Orexo US, INC. | $24.20 | 2019 | |
| Linus Health, INC. | $19.23 | 2023 | |
| Tonix Medicines, INC. | $17.64 | 2025 | Tonmya |
| Horizon Therapeutics Plc | $17.15 | 2022 | |
| Shire North American Group INC | $16.49 | 2019 | |
| Cequr Corporation | $15.88 | 2024 | Cequr Simplicity |
| Halozyme INC | $15.06 | 2023 | |
| Biodelivery Sciences International, INC. | $14.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$125.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Papa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.